Comparative Pharmacology
Head-to-head clinical analysis: PERCODAN DEMI versus ROXIPRIN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: PERCODAN DEMI versus ROXIPRIN.
PERCODAN-DEMI vs ROXIPRIN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Oxycodone is a full mu-opioid receptor agonist; aspirin inhibits cyclooxygenase (COX-1 and COX-2), reducing prostaglandin synthesis.
Roxiprin is a combination analgesic containing rofecoxib (a COX-2 selective NSAID) and paracetamol (acetaminophen, a centrally acting analgesic/antipyretic). Rofecoxib inhibits prostaglandin synthesis by selectively blocking cyclooxygenase-2, reducing pain and inflammation. Paracetamol inhibits cyclooxygenase in the central nervous system and modulates descending serotonergic pathways, providing analgesia and antipyresis.
1 tablet (oxycodone 2.25 mg/aspirin 325 mg) orally every 6 hours as needed for pain; maximum 4 tablets in 24 hours.
500 mg orally every 6 to 8 hours as needed for pain or fever; maximum 2000 mg per day.
None Documented
None Documented
Oxycodone: 3-4 hours; salicylate (aspirin): 2-3 hours at low doses, 15-30 hours at high doses; terminal half-life clinically relevant for dosing interval (q4-6h).
2.5 hours (prolonged to 4-6 hours in hepatic impairment; no significant change in renal impairment)
Renal: ~90% (oxycodone: ~60% as metabolites, ~10% unchanged; aspirin: ~80% as salicylates, ~10% unchanged). Biliary/fecal: minor.
Renal (70% as unchanged drug, 20% as glucuronide conjugate); biliary/fecal (10%)
Category C
Category C
Opioid Analgesic Combination
Opioid Analgesic Combination